Loading clinical trials...
Loading clinical trials...
Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Anti-CD14 Treatment in Hospitalized Patients With COVID-19
Conditions
Interventions
anti-CD14
Placebo
+1 more
Locations
5
United States
Sarasota Memorial Health Care System
Sarasota, Florida, United States
Virginia Mason Medical Center
Seattle, Washington, United States
Harborview Medical Center
Seattle, Washington, United States
Swedish Medical Center
Seattle, Washington, United States
University of Washington Medical Center-Montlake
Seattle, Washington, United States
Start Date
April 12, 2021
Primary Completion Date
February 4, 2022
Completion Date
February 4, 2022
Last Updated
June 26, 2023
NCT04425733
NCT05375760
NCT05249816
NCT04847141
NCT04742725
NCT04863547
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions